Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight
The congestive heart failure market is expected to witness steady growth over the coming years, driven by the rising prevalence of cardiovascular diseases, an aging global population, and increasing awareness of early diagnosis and disease management. In addition, the expected launch of emerging therapies such as Omecamtiv Mecarbil (Cytokinetics), Ziltivekimab (NN6018) (Novo Nordisk), CardiALLO Cell Therapy (BioCardia), Umiposgene Parvec (Bayer), and others will further propel the market growth.
LAS VEGAS, July 28, 2026 /PRNewswire/ -- Recently published Congestive Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, congestive heart failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Congestive Heart Failure Market Summary
Discover what is the future of the congestive heart failure drugs market @ https://www.delveinsight.com/report-store/congestive-heart-failure-market
Key Factors Driving the Growth of the Congestive Heart Failure Market
Aparna Thakur, Project Manager of Forecasting at DelveInsight, said that many clinical trials addressing the effects of drugs on HFpEF are underway, providing possible medical evidence for the future treatment of HFpEF
Congestive Heart Failure Market Analysis
Congestive Heart Failure Competitive Landscape
Some of the congestive heart failure drugs under development include Omecamtiv Mecarbil (Cytokinetics), Ziltivekimab (NN6018) (Novo Nordisk), CardiALLO Cell Therapy (BioCardia), CardiAMP Cell Therapy (BioCardia), CRD-740 (Cardurion Pharmaceuticals), Umiposgene Parvec (Bayer), AZD5462 (AstraZeneca), Vicadrostat (BI 690517)/empagliflozin (Boehringer Ingelheim), Rexlemestrocel-L (Mesoblast), AB-1002 gene therapy (AskBio), and others.
Cytokinetics' Omecamtiv mecarbil is a selective, small-molecule cardiac myosin activator designed to enhance cardiac contractile function by directly targeting the heart's pumping mechanism. It works by activating cardiac myosin, the motor protein that converts chemical energy into the mechanical force required for heart muscle contraction, thereby improving cardiac performance. Preclinical studies have demonstrated that cardiac myosin activators can enhance myocardial contractility without increasing intracellular calcium levels in cardiac muscle cells or elevating myocardial oxygen demand. Omecamtiv mecarbil has completed Phase III clinical evaluation for the treatment of congestive heart failure (CHF).
BioCardia's CardiAMP cell therapy is an investigational regenerative treatment designed to provide a comprehensive approach to managing heart failure. The therapy combines a proprietary molecular diagnostic to assess the regenerative potential of a patient's bone marrow cells and identify suitable candidates, along with a point-of-care cell processing system that prepares the cells at the patient's bedside before administration. The Phase IIIB CardiAMP HF II trial (NCT06258447) is currently enrolling participants across the United States. Additionally, the therapy has received Breakthrough Therapy Designation (BTD) from the US FDA for the treatment of heart failure.
The anticipated launch of these emerging therapies are poised to transform the congestive heart failure market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the congestive heart failure market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the congestive heart failure treatment devices market @ Congestive Heart Failure Drugs
Recent Developments in the Congestive Heart Failure Market
Congestive Heart Failure Epidemiology Segmentation
The congestive heart failure epidemiology section provides insights into the historical and current congestive heart failure patient pool and forecasted trends for the leading markets. In the 7MM, the US accounted for the highest number of diagnosed prevalent cases of heart failure, with nearly 7.4 million in 2025.
The congestive heart failure treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Congestive Heart Failure Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Congestive Heart Failure Market CAGR
8 %
Congestive Heart Failure Market Size in 2025
USD 9 Billion
Key Congestive Heart Failure Companies
Cytokinetics, Novo Nordisk, BioCardia, Cardurion Pharmaceuticals, Bayer, AstraZeneca, Boehringer Ingelheim, Mesoblast, AskBio, Lexicon Pharmaceuticals, Viatris, American Regent, Vifor, Daiichi Sankyo, scPharmaceuticals, Eli Lilly, and others
Key Congestive Heart Failure Therapies
Omecamtiv Mecarbil, Ziltivekimab (NN6018), CardiALLO Cell Therapy, CardiAMP Cell Therapy, CRD-740, Umiposgene Parvec, AZD5462, Vicadrostat (BI 690517)/empagliflozin, Rexlemestrocel-L, AB-1002 gene therapy, INPEFA, INJECTAFER/FERINJECT, FUROSCIX, JARDIANCE, and others
Scope of the Congestive Heart Failure Market Report
Download the report to understand the new device for congestive heart failure @ Congestive Heart Failure Clinical Trials
Table of Contents
1
Congestive Heart Failure Market Key Insights
2
Congestive Heart Failure Market Report Introduction
3
Executive Summary of Heart Failure
4
Key Events
5
Heart Failure Market Overview at a Glance
5.1
Clinical Landscape Analysis (By Phase, RoA, and Molecule Type)
5.2
Market Share (%) Distribution of Heart Failure by Therapies in 2025
5.3
Market Share (%) Distribution of Heart Failure by Therapies in 2036
6
Epidemiology and Market Forecast Methodology
7
Disease Background and Overview
7.1
Introduction
7.2
Causes of Heart Failure
7.3
Signs and Symptoms
7.4
Stages of Heart Failure
7.5
Classification of Heart Failure
7.6
Biomarkers for the Heart Failure
7.7
Diagnosis, Diagnostic Algorithm, and Differential Diagnosis
7.8
Diagnostic Guidelines
8
Treatment of CHF
8.1
Treatment Algorithm
8.2
Guidelines
9
Epidemiology and Patient Population of CHF
9.1
Key Findings
9.2
Assumptions and Rationale
9.3
Total Diagnosed Prevalent Cases of Heart Failure in the 7MM
9.4
The United States
9.4.1
Total Diagnosed Prevalent Cases of Heart Failure in the United States
9.4.2
Gender-specific Diagnosed Prevalent Cases of Heart Failure in the United States
9.4.3
Ejection Fraction-specific Diagnosed Prevalent Cases of Heart Failure in the United States
9.4.4
NYHA Class-specific Diagnosed Prevalent Cases of Heart Failure in the United States
9.4.5
Type-specific Diagnosed Prevalent Cases of Heart Failure in the United States
9.4.6
Age-specific Diagnosed Prevalent Cases of Heart Failure in the United States
9.5
EU4 and the UK
9.6
Japan
10
Patient Journey of CHF
11
Marketed Therapies of CHF
11.1
Competitive Landscape Summary
11.2
ENTRESTO (sacubitril and valsartan): Novartis and Otsuka Pharmaceutical
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Developmental Activities
11.2.4
Summary of Pivotal Trial
11.2.5
Safety and Efficacy
11.2.6
Analyst Views
11.3
JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly
11.4
VERQUVO (vericiguat): Bayer and Merck
11.5
FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
12
Emerging Therapies of CHF
12.1
Competitive Landscape Summary
12.2
Omecamtiv Mecarbil: Cytokinetics
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.3.1
Clinical Trial Information in Heart Failure
12.2.4
Safety and Efficacy
12.2.5
Analyst Views
12.3
Ziltivekimab (NN6018): Novo Nordisk
12.4
CardiALLO Cell Therapy: BioCardia
12.5
CardiAMP Cell Therapy: BioCardia
13
Heart Failure Market: Seven Major Market Analysis
13.1
Key Findings
13.2
Congestive Heart Failure Market Outlook
13.3
Conjoint Analysis
13.4
Key Congestive Heart Failure Market Forecast Assumptions
13.5
Total Market Size of Heart Failure in the 7MM
13.6
The United States Congestive Heart Failure Market Size
13.6.1
Total Market Size of Heart Failure in the United States
13.6.1
Total Market Size of Heart Failure in the United States
13.6.2
Market Size of Heart Failure by Therapies in United States
13.7
EU4 and the UK Congestive Heart Failure Market Size
13.8
Japan Congestive Heart Failure Market Size
14
Unmet needs of Heart Failure
15
SWOT Analysis of Heart Failure
16
KOL Views
17
Market Access and Reimbursement
17.1
The United States
17.2
EU4 and the UK
17.3
Japan
17.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
17.5
Heart Failure Market Access and Reimbursement
18
Bibliography
19
Congestive Heart Failure Market Report Methodology
Related Reports
Congestive Heart Failure Treatment Devices Market
Congestive Heart Failure Treatment Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key CHF treatment devices companies, including GE HealthCare, Boston Scientific Corporation, Medtronic, Abbott, Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and others.
Chronic Heart Failure Market
Chronic Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key chronic heart failure companies, including Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, and others.
Acute Heart Failure Market
Acute Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute heart failure companies, including Arena Pharmaceuticals, AstraZeneca, Palatin Technologies, Inc, Boehringer Ingelheim, Eli Lilly and Company, Aventyn, Inc., Corthera, Inc, Idorsia Pharmaceuticals Ltd., The Medicines Company, Bristol-Myers Squibb, Cardioxyl Pharmaceuticals, Inc, Nile Therapeutics, Trevena Inc., Scios, Inc., Novartis, and others.
Advanced Heart Failure Market
Advanced Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced heart failure companies, including Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP